Search results for " titer" in Articles / App Notes

Article Digitalization: The Route to Biopharma 4.0
The strategy was designed to handle deviations in titer from 1 g/L to 7 g/L by selecting a pre-programmed set of methodologies designed as per the requirements. In another study, integrated process mo…

Article Simple Fed-Batch Process Development for a Knockout Cell Line
CLICK HERE TO READ MORE >> This workflow improved titers by 500% compared with Chinese hamster ovary cell culture in basal medium.

Article Updating Viral Clearance for New Biologic Modalities
“If viruses are similar in size to the pore size of the VRF membrane, the extent to which a filter can reduce virus titer depends on the flow conditions applied to the VRF. Interrupting flow can exace…

Article Improving mAb Manufacturing Productivity by Optimizing Buffer and Media Prep Process Flow
A typical monoclonal antibody (mAb) process may require 2000 L of a buffer and more than 100,000 L per batch based on titer and bioreactor volume (1, 2). As a result, the variety of buffer solutions u…

Article Improving Upstream Predictability
“We’ve consistently been seeing titers in the range of 4–6 g/L in [monoclonal antibody] mAb fed-batch processing within a chemically defined media environment. This environment, in turn, results in mo…

Article Maximizing the Effectiveness of Upstream Bioprocessing Through the Combination of Lab Informatics and Instrumentation
Novel techniques including Raman spectroscopy and other advanced monitoring methods have the potential to reduce the reliance on discrete sampling points for off-line analytics such as titer measureme…

Article Mapping a Route for Cell and Gene Therapy Process Development
The productivity largely depends on the harvest titer and downstream process yield. Moreover, the product design at the molecular level, the producer cell line, and the production medium can all be li…

Article Best Practices for Selecting a Top-Quality Cell Line
Defining high-quality cell lines A high-quality cell line will demonstrate high stability, scalability, and high titer, so that it can provide reproducible results—with all product quality attribu…

Article Emerging Therapies Test Existing Bioanalytical Methods
To prevent these pre-existing antibodies from interfering with the program, it is recommended to pre-screen the sample population, and often individuals with high titers of antibodies are excluded fro…

Article Development of Purification for Challenging Fc-Fusion Proteins
In response, titers for monoclonal antibodies (mAbs) and Fc-fusion proteins have significantly increased (1-5). Particularly for Fc-fusion proteins, these improvements have resulted in a …

Show All Results

Previous PageNext Page